Business context and reporting period
The supplied filing is Sharps Technology, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024—not a filing identified as Skyai, Inc. Investors should verify the issuer identity before relying on this summary. Sharps is a pre-revenue medical-device company developing and commercializing safety syringes; it reports no revenue or operating cash flow since inception.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.844 million | $2.318 million |
| Net loss | $982,386 | $2.112 million |
| Basic and diluted loss per share | $0.05 | $0.20 |
| Cash used in operating activities | $1.889 million | $2.063 million |
| Cash at period end | $1.166 million | $3.013 million at Dec. 31, 2023 |
R&D expense fell 41% to $197,439 and general and administrative expense fell 17% to $1.647 million. A $850,057 non-cash gain from remeasuring warrant liabilities contributed to the lower net loss; the comparable gain was $184,085. Comprehensive loss was $1.200 million, including a $218,053 foreign-currency translation loss. Gross margin and other operating margins are not meaningful because the company reported no revenue.
At March 31, current assets were $3.211 million and current liabilities were $2.781 million, producing working capital of $429,448, down from $1.146 million at year-end. Total assets were $9.804 million, total liabilities $2.943 million, and stockholders’ equity $6.861 million. The filing reports no conventional debt balance; current liabilities include a $1.573 million fair-value warrant liability. Cash and cash equivalents were $1.166 million. Inventory was $1.842 million and net fixed assets were $6.471 million.
Material changes versus the prior comparable period
- Net loss narrowed by approximately 53%, reflecting lower operating expenses and a larger warrant fair-value gain.
- Operating cash use declined by $173,355, but the company had a net cash decrease of $1.847 million in the quarter. Financing provided only $396, compared with $3.239 million in Q1 2023.
- Cash declined $1.847 million from December 31, 2023. Working capital also declined by approximately $716,000.
- Common shares outstanding increased from 15,274,457 at year-end to 15,670,898 at March 31, primarily due to exercise of pre-funded warrants.
Outlook, commentary, risks and unusual items
Management states that working capital is insufficient to fund planned operations for the next 12 months and that substantial doubt exists about the company’s ability to continue as a going concern. Continued operations and commercialization depend on raising additional financing, which management expects to seek through equity sales and/or other financing. The filing provides no quantified revenue, earnings, or cash-flow guidance.
Sharps says it is manufacturing commercial quantities and building inventory. It reported receiving its first Securegard purchase order for South America and anticipates further orders in 2024, but has not generated revenue to date. A March 2024 agreement appoints Roncadelle as an exclusive distributor of its products in specified international regions and Sharps as exclusive distributor of Roncadelle products in the Americas. The company is negotiating with Owens & Minor for logistics services planned to begin in Q3 2024. The proposed purchase of equipment and leasehold improvements at Nephron’s South Carolina facility remains contingent on obtaining financing, with no assurance it will close. Management says commercialization of the Provensa line remains delayed and that it cannot determine a final commercialization timeline.
Warrant liabilities are remeasured at fair value, and the resulting gains or losses can materially affect reported results without reflecting operating cash generation. The company disclosed 20.676 million warrants outstanding at quarter-end and 23.085 million options and warrants potentially dilutive in the future that were excluded from diluted EPS as anti-dilutive. A subsequent event: on April 26, 2024, the company granted options to purchase 1.395 million shares. The filing reports no material litigation, no material changes to previously disclosed risk factors, and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the provided document names Sharps Technology, Inc., whereas the request metadata names Skyai, Inc.
- Assess funding needs and the going-concern warning against cash, working capital, and ongoing quarterly operating cash use.
- Verify whether planned financing, the Nephron facility transaction, and the Owens & Minor logistics arrangement progress or close.
- Track whether the Roncadelle relationship and reported purchase order convert into recognized revenue and repeat orders.
- Evaluate potential dilution from outstanding warrants, options, and the April 2024 option grant, as well as the volatility of warrant fair-value adjustments.